Review article: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 11, 2000, Pages 1403-1409

  Papa, A ^a   Danese, S ^a   Gasbarrini, A ^a   Gasbarrini, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; STEROID;

ALOPECIA; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; COLON HEMORRHAGE; DRUG MECHANISM; ENTERITIS; EOSINOPHILIA; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; OSTEOPOROSIS; PRIORITY JOURNAL; REMISSION; STEROID THERAPY; THROMBOCYTOPENIA; VAGINA BLEEDING;

ANTICOAGULANTS; CLINICAL TRIALS; HEPARIN; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 0033678918     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00860.x     Document Type: Article

References (70)

1. Early mucosal changes in Crohn's disease
2. Pathogenesis of Crohn's disease: Multifocal intestinal infarction
3. Mucosal capillary thrombi in rectal biopsies
4. Inherited disorders of coagulation appear to protect against inflammatory bowel disease
5. Thrombotic vascular risk factors in inflammatory bowel disease
6. Thromboembolism in inflammatory bowel disease: Role of platelets
7. Hemostatic abnormalities in inflammatory bowel disease
8. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease
9. Prevalence and significance of anticardiolipin antibodies in Crohn's disease
10. Free protein C deficiency in patients with Crohn's disease
11. Response to heparin in patients with ulcerative colitis
12. Paradoxical response to heparin in 10 patients with ulcerative colitis
13. Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases
14. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease
15. Heparin in the treatment of highly active inflammatory bowel disease
16. Treatment of active Crohn's disease with heparin
17. Heparin therapy in refractory ulcerative colitis - An update
18. Treatment of ulcerative colitis with heparin
19. Treatment of corticosteroid resistant ulcerative colitis with heparin - A report of 9 cases
20. Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: A pilot study
21. The use of anticoagulants in combined therapy in non-specific ulcerative colitis
22. Hemostasis and heparin therapy in non-specific ulcerative colitis
23. Pharmacodynamics, clinical indications and adverse effects of heparin
24. Heparin-induced thrombocytopenia
25. Heparin-induced thrombocytopenia: Towards consensus
26. Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy
27. The effects of long-term heparin therapy during pregnancy on bone density
28. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
29. A prospective study of heparin-induced osteoporosis in pregnancy rising bone densitometry
30. Histophometric evaluation of reversible heparin induced osteoporosis in pregnancy
31. Inflammatory bowel disease and osteoporosis
32. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
33. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis
34. IBD: A vascular disorders? The case for heparin therapy
35. Vascular endothelial cells are susceptible to deavage by neutrophils
36. Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin
37. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins
38. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
39. Heparin regulates ICAM-1 expression in human endothelial cells: An example of noncytokine-mediated endothelial activation
40. Heparin and heparan sulphate are inhibitors of human leukocyte elastase
41. Immunomodulating activity of heparin
42. Therapeutic uses of heparin beyond its traditional role as anticoagulant
43. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production
44. Effect of growth factors on cell proliferation and epithelization in human skin
45. Growth factors: New 'endogenous drugs' for ulcer healing
46. Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing
47. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
48. A dual receptor system is required for basic fibroblast growth factor activity
49. Biology of the syndecans: A family of transmembrane heparan sulphate proteoglycans
50. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy
51. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease
52. Mediators of mucosal inflammation: Implications for therapy
53. Inflammatory mediators in inflammatory bowel disease
54. Cytokines in inflammatory bowel disease
55. Heparin inhibits the expression of interleukin-11 and granulocyte-macrophage colony-stimulating factor in primate bone marrow stromal fibroblasts through mRNA destabilization
56. Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents
57. On the binding of tumor necrosis factor to heparin and the release in vivo of the TNF-binding protein 1 by heparin
58. Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin
59. Serum interleukin-6 is related to disease activity but not specificity in inflammatory bowel disease
60. Is nitric oxide and heparin treatment justified in inflammatory bowel disease? An experimental study
61. Heparin and low molecular weight heparin decrease nitric oxide production by human polymorphonuclear cells
62. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease
63. Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes
64. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents
65. Location of superoxide anion generation in human colonic mucosa obtained by biopsy
66. The role of reactive oxygen metabolites in ulcerative colitis
67. Heparin and inflammatory bowel disease
68. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression
69. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro
70. A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis